Literature DB >> 8995991

Exhaled nitric oxide during exercise in primary pulmonary hypertension and pulmonary fibrosis.

M S Riley1, J Pórszász, J Miranda, M P Engelen, B Brundage, K Wasserman.   

Abstract

STUDY
OBJECTIVES: Nitric oxide (NO), a potent vasodilator, is present in the exhaled air of humans. We wished to quantify NO production in patients with abnormalities of the pulmonary circulation. PARTICIPANTS: Nine patients with primary pulmonary hypertension (PPH), six with pulmonary fibrosis (PF), and 20 normal volunteers were studied.
INTERVENTIONS: All subjects were studied at rest and during continuous incremental (ramp) cycle ergometry exercise. All patients with PPH and nine matched normal volunteers also performed constant exercise at equal absolute work rates. MEASUREMENTS AND
RESULTS: The concentration of NO was measured continuously in mixed expired air, and the rate of NO production (VNO) calculated. Peak exercise capacity was markedly impaired in both patient groups. VNO was similar at rest in the PPH patients (142 +/- 84 nL/min) and the normal subjects (117 +/- 45 nL/min), but lower in the PF patients (66 +/- 13 nL/min; p < 0.05; analysis of variance with Bonferonni correction). While VNO in normal subjects more than doubled by peak exercise to 268 +/- 85 nL/min, there was no significant rise with exercise in either patient group (PPH, 155 +/- 81 nL/min; PF, 91 +/- 67 nL/min). Constant work rate exercise induced a significant rise in VNO in the normal subjects (rest, 101 +/- 68 nL/min; exercise, 147 +/- 87 nL/min; p < 0.001) but no significant change in the PPH patients (rest, 127 +/- 111 nL/min; exercise, 68 +/- 65 nL/min).
CONCLUSIONS: We conclude that the low resting VNO in PF may be due to loss of normal functional pulmonary capillary bed. The increase in VNO seen in normal subjects may be associated with dilatation and recruitment of the pulmonary capillary bed during exercise, and failure to increase VNO during exercise in disease states may reflect an inability to recruit the capillary bed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8995991     DOI: 10.1378/chest.111.1.44

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

Review 1.  Primary pulmonary hypertension in childhood.

Authors:  S G Haworth
Journal:  Arch Dis Child       Date:  1998-11       Impact factor: 3.791

Review 2.  Exhaled nitric oxide measurements: clinical application and interpretation.

Authors:  D R Taylor; M W Pijnenburg; A D Smith; J C De Jongste
Journal:  Thorax       Date:  2006-09       Impact factor: 9.139

Review 3.  Treatment-related biomarkers in pulmonary hypertension.

Authors:  Aparna C Swaminathan; Alex C Dusek; Tim J McMahon
Journal:  Am J Respir Cell Mol Biol       Date:  2015-06       Impact factor: 6.914

4.  Fractional Exhaled Nitric Oxide Measurement in Pulmonary Hypertension: A Follow-Up Study.

Authors:  Nilay Orak Akbay; Zuleyha Bingol; Esen Kiyan; Ekrem Bilal Karaayvaz; Ahmet Kaya Bilge; Halim Issever; Gulfer Okumus
Journal:  Clin Appl Thromb Hemost       Date:  2017-04-10       Impact factor: 2.389

5.  Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction.

Authors:  Roshan P Weerackody; David J Welsh; Roger M Wadsworth; Andrew J Peacock
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-06       Impact factor: 4.733

Review 6.  Multiple roles of nitric oxide in the airways.

Authors:  F L M Ricciardolo
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

7.  Riociguat: PATENT-1 Study.

Authors:  Karim Said
Journal:  Glob Cardiol Sci Pract       Date:  2014-06-18

8.  Analysis of volatile compounds in exhaled breath condensate in patients with severe pulmonary arterial hypertension.

Authors:  J K Mansoor; Edward S Schelegle; Cristina E Davis; William F Walby; Weixiang Zhao; Alexander A Aksenov; Alberto Pasamontes; Jennifer Figueroa; Roblee Allen
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

Review 9.  Update on the Mechanisms of Pulmonary Inflammation and Oxidative Imbalance Induced by Exercise.

Authors:  O F Araneda; T Carbonell; M Tuesta
Journal:  Oxid Med Cell Longev       Date:  2016-01-05       Impact factor: 6.543

10.  Exhaled nitric oxide is not a biomarker for idiopathic pulmonary arterial hypertension or for treatment efficacy.

Authors:  Majid Malekmohammad; Gert Folkerts; Babak Sharif Kashani; Parisa Adimi Naghan; Zahra Habibi Dastenae; Batoul Khoundabi; Johan Garssen; Esmaeil Mortaz; Ian M Adcock
Journal:  BMC Pulm Med       Date:  2019-10-29       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.